Long COVID — its official medical designation is Post-acute sequelae SARS-CoV-2, or PASC — is known to affect up to 30 percent of patients who are infected with the virus. But how well does the vaccine prevent people with breakthrough cases from facing long-term symptoms such as chronic fatigue or a loss of smell and taste?
Research to date suggests that it cuts the risk by about half, though experts caution that more studies are needed to get the full picture. Still, it's mostly good news. “The evidence is mounting that it’s likely to be protective against long COVID,” says William Li, president and founder of the Angiogenesis Foundation “I'm so glad that I am fully vaccinated.”
When COVID-19 first made its appearance in early 2020, Li and his team were focused on the nonprofit's core research involving blood vessels and their affect on health. Within the year's first quarter, ...
